Outcomes in patients with nontriple antiphospholipid syndrome (APS) anticoagulated with rivaroxaban
Thura Win Htut
Department Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK
Search for more papers by this authorDenis Milne
Department Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK
Search for more papers by this authorMohammed M. Khan
Department Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK
Search for more papers by this authorCorresponding Author
Henry G. Watson
Department Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK
Correspondence
Henry G Watson, Consultant Haematologist and Honorary Professor of Medicine, Department of Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen AB25 2ZN, UK.
Email: [email protected]
Search for more papers by this authorThura Win Htut
Department Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK
Search for more papers by this authorDenis Milne
Department Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK
Search for more papers by this authorMohammed M. Khan
Department Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK
Search for more papers by this authorCorresponding Author
Henry G. Watson
Department Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK
Correspondence
Henry G Watson, Consultant Haematologist and Honorary Professor of Medicine, Department of Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen AB25 2ZN, UK.
Email: [email protected]
Search for more papers by this author
REFERENCES
- 1Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019; 78(10): 1296-1304.
- 2Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000; 15(2): 145-151.
- 3Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012; 157(1): 47-58.
- 4Lackner KJ, Müller-Calleja N. Laboratory criteria for antiphospholipid syndrome: comment. J Thromb Haemost. 2018; 16(10): 2115-2116.
- 5Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost. 2005; 3(6): 1160-1165.
- 6Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018; 132(13): 1365-1371.
- 7Cohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016; 3(9): e426-e436.
- 8Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4): 692-694.
- 9Vlachoyiannopoulos PG, Routsias JG. A novel mechanism of thrombosis in antiphospholipid antibody syndrome. J Autoimmun. 2010; 35(3): 248-255.
- 10van Os GM, Meijers JC, Agar C, et al. Induction of anti-beta2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost. 2011; 9(12): 2447-2456.
- 11Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020; 18(9): 2126-2137.
- 12Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13): 1206-1214.
